contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


mendus-vididencel-induced-anti-tumor-immune-responses-in-ovarian-cancer

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Analyst

Antti Siltanen

Mendus is active in medical technology. The company produces therapeutic vaccines used in the field of oncology. The company mainly drives development in immunotherapy with a focus on the treatment of serious tumors. Examples of diseases that the products are used against include kidney and liver cancer. The largest activity is found within the Nordic market. The company previously went by the name Immunicum and today has its headquarters in Stockholm.

Mendus

Mendus announced on Thursday that the company will present new clinical data on vididencel for ovarian cancer at the ESMO Gynaecological Cancers Annual Congress. 

Mendus <a href="https://www.inderes.fi/releases/alison-trial-data-presented-at-esmo-gynaecological-cancers-demonstrate-tumor-directed-immune-responses-in-the-majority-of-patients-treated-with-vididencel">announced</a> on Thursday that the company will present new clinical data on vididencel for ovarian cancer at the ESMO Gynaecological Cancers Annual Congress. The Phase I ALISON trial has met its primary objective of inducing tumor-directed immune responses in at least 10 patients (of 15) treated with vididencel. The company expects a primary read-out of the ALISON trial of all treated patients (17) in Q4&#x2019;24.
<h2>10 patients showed tumor-directed immune responses following vididencel administration</h2>
ALISON is a Phase I clinical trial studying vididencel, Mendus&#x2019; cellular cancer immunotherapy, for ovarian cancer. The trial was fully enrolled with 17 patients as of April 2024. According to the new data, 10 out of 15 patients showed tumor-directed immune responses following vididencel administration. According to the announcement, 3 patients did not reach a vaccine-induced response (VIR) due to high baseline responses. In terms of adverse events, the results are in line with the previous understanding of vididencel having a very favorable safety/tolerability profile. The adverse events were mild and predominantly at the site of injection. At week 22 of the trial, 10 patients had stable disease and 7 had cancer recurrence confirmed by imaging. The ALISON trial will continue to follow up on the patients to gain more insight into the possible clinical benefit. Confirmation of whether vididencel leads to prolonged survival in patients with ovarian cancer still requires further research. 
The new data will be presented at the ESMO Gynaecological Cancers Annual Congress, on June 20-22, 2024 in Florence, Italy. The poster will be available on Mendus&#x2019; website after the presentation.

Inderes

Mendus: Vididencel-induced anti-tumor immune responses in ovarian cancer

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

Valuation methods: DCF model

What a stock picker should understand about the new mandatory corporate sustainability (CSRD) reports, part 1.

The DuPont formula helps understand the dynamics of value creation